Why LYMPHOSEEK?
In October 2014, the FDA approved the expanded use of LYMPHOSEEK as a lymphatic mapping agent for solid tumors where it is a component of the intraoperative procedure.
Designed to identify
LYMPHOSEEK allows for timely and precise identification of tumor-draining lymph nodes.2,3
Hear from peers
Join one of our upcoming webinars to hear from peers about advances in lymphatic mapping and sentinel lymph node biopsy with LYMPHOSEEK. You will hear about patient case studies and learn results from clinical trials as well as have the opportunity to ask our presenters questions about their clinical experience with LYMPHOSEEK.
30-day trial results
In a 30-day trial of LYMPHOSEEK, Mercy Medical Center observed short procedure times and low pain scores while adding new surgical cases.
References: 1. LYMPHOSEEK Injection [prescribing information]. Dublin, OH: Cardinal Health; June 2019. 2. Sondak V, King DW, Zager JS, et al. Combined analysis of Phase III trials evaluating Tc99m tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol 2013;20:680-8. 3. Wallace AM, Han LK, Povoski SP, et al. Comparative evaluation of [99mTc] tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two Phase 3 trials. Ann Surg Oncol. 2013;20:2590-9.)